Boston Scientific
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $4,209,000 | $4,120,000 | $3,856,000 | $3,725,000 |
Gross Profit | 2,897,000 | 2,585,000 | 2,647,000 | 2,578,000 |
EBITDA | 1,054,000 | 812,000 | 984,000 | 883,000 |
EBIT | 748,000 | 501,000 | 680,000 | 570,000 |
Net Income | 468,000 | 324,000 | 492,000 | 505,000 |
Net Change In Cash | 4,209,000 | 4,120,000 | 3,856,000 | 3,725,000 |
Free Cash Flow | 698,000 | 658,000 | -81,000 | 690,000 |
Cash | 2,502,000 | 2,988,000 | 2,329,000 | 865,000 |
Basic Shares | 1,487,400 | 1,484,200 | 1,481,700 | 1,476,900 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $14,240,000 | $12,682,000 | $11,888,000 | $9,913,000 |
Gross Profit | 9,895,000 | 8,679,000 | 8,128,000 | 6,403,000 |
EBITDA | 3,453,000 | 2,741,000 | 2,518,000 | 1,511,000 |
EBIT | 2,257,000 | 1,605,000 | 1,425,000 | 389,000 |
Net Income | 1,593,000 | 698,000 | 1,041,000 | -140,000 |
Net Change In Cash | 14,240,000 | 12,682,000 | 11,888,000 | 9,913,000 |
Cost of Revenue | -1,033,000 | 178,000 | 1,390,000 | |
Free Cash Flow | 1,703,000 | 914,000 | 1,316,000 | 1,132,000 |
Cash | 865,000 | 928,000 | 1,925,000 | 1,734,000 |
Basic Shares | 1,463,500 | 1,439,700 | 1,433,800 | 1,416,700 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.63 |
2024-06-30 | $0.62 |
2024-03-31 | $0.56 |
2023-12-31 | $0.55 |
